CSL624, Capsule (placebo matching vamifeport) clinical trials

A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study of the Efficacy and Safety of Vamifeport in Adult Subjects with HFE-related Hereditary Hemochromatosis (FERROCLEAR Study)

This study is testing a new medicine, Vamifeport, for adults with a condition called hereditary hemochromatosis. It aims to see if the medicine can reduce high iron levels in the liver and if it's safe to use.